The use of FLT3 inhibitors (FLT3i) for the treatment of acute leukemias mainly concerns AML, which represents nowadays a treatment paradigm for FLT3-mutated patients [68,129]. This evidence concerns the gene FLT3 and acute myeloid leukemia.